Showing results (201-210 of 222) with videos related to
Sort By:
Pageof 23
Annals of Biomedical Engineering|October 11, 2018
Health-Related Quality of Life Following Concussion in Collegiate Student-Athletes With and Without Concussion HistoryM L Weber, R C Lynall, N L Hoffman, et al.Scientific Reports|March 11, 2021
Mutation spectrum of NOD2 reveals recessive inheritance as a main driver of Early Onset Crohn's DiseaseJulie E Horowitz, Neil Warner, Jeffrey Staples, et al.Journal of the American Academy of Dermatology|July 7, 2026
Dupilumab treatment improves linear growth and bone biomarkers in children with atopic dermatitis: Post hoc analysis of a phase 3 randomized, placebo-controlled clinical trial and an open-label extension studyAlan D Irvine, Amy S Paller, Elaine C Siegfried, et al.Physical Review Letters|November 13, 2009
Ferroelectricity in ultrathin BaTiO3 films: probing the size effect by ultraviolet Raman spectroscopyD A Tenne, P Turner, J D Schmidt, et al.Allergy|May 15, 2026
Type-2-Inflammatory-Diseases Share Comorbidities, Molecular Signatures, IL4/IL13 Genetics, and Response to IL4/IL13 BlockadeJennifer D Hamilton, Manuel A R Ferreira, Wei Keat Lim, et al.The Journal of Allergy and Clinical Immunology|April 24, 2026
Dupilumab normalizes the eosinophilic esophagitis disease transcriptomeWei Keat Lim, Matthew F Wipperman, Marc E Rothenberg, et al.The Journal of Urology|January 1, 1983
A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral areaM S Soloway, S Beckley, M F Brady, et al.The Journal of Urology|May 1, 1983
Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancerS A Loening, S Beckley, M F Brady, et al.Journal of Surgical Oncology|June 1, 1983
The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostateR P Gibbons, S Beckley, M F Brady, et al.Science Translational Medicine|October 29, 2025
The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthmaSeblewongel Asrat, Wei Keat Lim, Subhashini Srivatsan, et al.Pageof 23